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1. Introduction 
Aneuploidy can be defined as extra or missing whole chromosomes in the nucleus of a cell 
and occurs during cell division when chromosomes do not separate equally between the 
two new daughter cells (Hassold & Hunt 2001). Chromosome imbalance typically results in 
non-viability, manifesting as developmental arrest prior to implantation, miscarriage or 
stillbirth. Depending on the chromosomes involved, aneuploidy can also result in viable but 
developmentally abnormal pregnancies e.g. Down or Klinefelter Syndrome.  In all cases, 
aneuploidy results in a non-favourable outcome for the family in question and is 
undoubtedly a major contributing factor to the relatively low fecundity of humans when 
compared with other species. 
Aneuploidy is a particularly frequent event during both human gametogenesis and early 
embryogenesis in humans and arises due to mal-segregation of the chromosomes. The most 
cited mechanism is classical “non-disjunction” however this has been challenged in recent 
years and alternative mechanisms have been proposed (see subsequent sections). It is 
estimated that at least 20% of human oocytes are aneuploid, a number that increases 
dramatically with advancing maternal age over the age of 35 years (Dailey et al. 1996a; 
Hassold & Hunt 2001). Conversely, the incidence of aneuploidy in sperm cells from a 
normal fertile male is estimated to be as low as 4-7% (Martin et al. 1991; Shi & Martin 2000). 
However, this can significantly increase in some cases of severe male factor infertility.  
The idea of screening pre-implantation embryos to eliminate the aneuploid ones is not new, 
but the ability to do this effectively has required rapid evolution of diagnostic technologies to 
combine speed, accuracy and reliability. To date, only direct analysis of chromosomes from 
cells in gametes and pre-implantation embryos (rather than indirect methods such as 
metabolic analysis) has proved successful in accurately detecting aneuploidy. Performing 
Preimplantation Genetic Screening (PGS) in this way involves the biopsy of cellular material 
from the embryo or oocyte at different stages of development. Since embryo biopsy is too 
invasive a procedure for routine embryo selection, PGS remains a test for high-risk patient 
groups only rather than for routine universal application. Worldwide, the test is only offered 
routinely to patients presenting with advanced maternal age, recurrent miscarriage, recurrent 
implantation failure and in some cases of severe male factor infertility. Due to the invasive 
nature of embryo biopsy and the complexity of human aneuploidy in the human IVF embryo, 
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cost benefit analysis is crucial to achieve positive outcomes. It could be argued that, in the past, 
the practice of PGS has not given proper concern to these issues and thus, going forward, 
patient selection and understanding the mechanisms of aneuploidy should be central to an 
effective PGS strategy. This chapter explores the premise underpinning the use of PGS in 
human embryos, its clinical applications, current methodologies and future applications. 
2. Origin of aneuploidy 
Aneuploidy in pre-implantation IVF embryos (and presumably also those naturally 
conceived) primarily arises during three developmental stages: (i) pre-meiotic divisions of 
gametogenesis; (ii) meiotic divisions of gametogenesis and (iii) early mitotic divisions of 
embryogenesis. Understanding the mechanism behind the mal-segregation of chromosomes 
at these stages gives insight into the limitations of PGS when applied clinically.  
2.1 Gonadal mosaicism 
Errors in germ cell proliferation or errors inherited in an otherwise somatically normal 
individual resulting in germ cell aneuploidy (gonadal mosaicism) can also contribute to 
aneuploidy of the gametes. This is perhaps the least studied of the three stages. In any event, 
the outcome is a hyper- or hypo- gamete and thus can be considered in the same way as a 
meiotic error. 
2.2 Meiosis 
Meiosis is the production of a haploid gamete by two specialised cell divisions in which the 
diploid chromosome complement of normal somatic cells is reduced (a requisite for sexual 
reproduction). Errors in chromosome segregation during these divisions typically result in 
gamete aneuploidy and subsequent ‘uniform’ aneuploidy in any resulting embryo. 
Although the basic principle of chromosome mal-segregation holds for both male and 
female meiosis in humans, the processes and resulting gametes are vastly different. Female 
meiosis, the process by which a single diploid germ cell develops into a single haploid 
ovum, involves two unequal meiotic divisions producing a mature ovum and two non-
functional products containing mirror images of the chromosomes present in the ovum. 
These are known as polar bodies (PB) and, once extruded, take no further part in 
development thus making them a useful sample for inferring chromosome constitution of 
the oocyte itself. Failures in female meiosis make, by far, the biggest contribution to 
aneuploidy in human pre-implantation embryos. Cytogenetic studies on oocytes and first 
polar bodies (PB1) from assisted conception cycles have shown more than 20% of oocytes 
from patients with an average age under 35 to be aneuploid (Selva et al. 1991; Fragouli et al. 
2006). The percentage of aneuploid oocytes increases significantly with age and has been 
shown to affect an average of around 70% of oocytes for patients of advanced maternal age 
(Van Blerkom 1989; Angell et al. 1993; Kuliev et al. 2003; Gutierrez-Mateo et al. 2004; Kuliev 
et al. 2005). 
There is conflicting evidence on the frequency of errors in both the first and second meiotic 
division with groups showing errors in both the first meiotic division-MI (Kuliev et al. 2003) 
and more recently in the second meiotic division-MII (Fragouli et al. 2011; Handyside et al. 
2012) occurring more frequently. This discrepancy may be due in part to differences in 
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patient maternal age of the study groups and the difference in resolution of the cytogenetic 
techniques used.  Either way, it is clear that chromosome segregation errors occur at 
significant rates during both the first and second meiotic divisions of oogenesis. 
Based on studies of yeast, drosophila and mouse models it was generally believed that 
aneuploidy arose as a result of classic nondisjunction and involved the segregation of a 
whole chromosome to the same pole as its homologue during meiosis. Studies of human 
oocytes led to an alternative model for the origin of aneuploidy (Angell 1991) suggesting 
that errors in meiosis can result in extra or missing chromatids (known as premature or 
precocious separation of sister chromatids - PS), as well as whole chromosomes in the 
daughter cells (See figure 1). Early studies of human oocytes supporting the hypothesis that 
precocious separation was the predominant mechanism leading to human aneuploidy were 
subject to recurring criticism (Angell 1991; Angell et al. 1993; Angell et al. 1994; Pellestor et al. 
2002; Kuliev et al. 2003). It was argued that use of ‘failed IVF’ oocytes‘ prolonged time in 
culture, sub-optimal metaphase preparation technique, and lack of rigour in the analysis 
may have led to interpretation errors (Dailey et al. 1996b; Lamb et al. 1996; Lamb et al. 1997; 
Mahmood et al. 2000). Recently several groups, including our own, performed analyses 
using methodology less prone to these confounding criticisms - the results of which support 
the hypothesis. Quantitative analysis of loss or gain of all 24 chromosomes on PB1 (Gabriel 
et al. 2011b) and sequential 24 chromosome analysis of PB1, PB2 and zygote performed on 
freshly harvested oocytes used in IVF treatments (Geraedts et al. 2011) have shown PS to be 
the predominant mechanism of chromosome mal-segregation in assisted reproduction 
derived oocytes. This is consistent with recent data exploring the decline of adhesion 
molecules holding sister chromatids together during anaphase arrest leading to increased PS 
events (Chiang et al. 2010; Lister et al. 2010). 
In contrast to oogenesis, male meiosis results in four equivalent functional spermatozoa 
from a single progenitor germ cell. The presence of typically millions of sperm per ejaculate 
make them easy to study en masse however it is impossible, with current technology, to 
screen a sperm head for aneuploidy then subsequently use it for PGS. This is because 
aneuploidy assessment of a sperm cell inevitably results in its destruction, and unlike in the 
ovum, there are no by-products available from which a determination of chromosome 
complement can be inferred. 
The overall incidence of aneuploidy in sperm is estimated to be around 4-7% (Martin et al. 
1991; Shi & Martin 2000) although some studies suggest it is as high as 14% in some infertile 
men (Johnson 1998; Shi & Martin 2001). Spermatogenesis can theoretically continue 
unchanged throughout the life of a man however several studies have shown there to be a 
correlation between increased sperm aneuploidy and advanced paternal age (Griffin et al. 
1995; Robbins et al. 1995) albeit not as dramatic as in the female. Other factors such as male 
factor infertility, smoking and chemotherapy can however increase sperm aneuploidy 
levels, making individual couples in which these risk factors are present possible candidates 
for PGS. 
2.3 Mitosis 
Mitosis is the process by which a diploid cell usually divides into two chromosomally 
identical daughter cells. It is the primary mechanism by which a multicellular individual  
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Fig. 1. Diagrammatic representation of classic nondisjunction (A) and premature separation 
of the sister chromatids (B), the two predominant mechanisms by which aneuploidy can 
arise in the first meiotic division in humans. 
develops from a single fertilised oocyte (zygote). Human mitotic divisions are generally not 
prone to chromosome segregation errors to any great extent, except in the case of early 
embryo cleavage stages where cells are thought to be exquisitely prone to segregation errors 
(Bean et al. 2001).  Indeed, recent studies using a variety of cytogenetic techniques on early 
IVF human embryos have demonstrated that over 50% are subject to some form of mitotic 
error (Bielanska et al. 2002; Munne et al. 2004; Delhanty 2005; Munne 2006). 
Most mitotic errors in early embryo development will lead to chromosomal mosaicism which 
is defined as the presence of two or more chromosome complements within an embryo 
developed from a single zygote.  There are three hypothesised mechanisms by which mitotic 
aneuploidy can arise: (i) chromosome loss (presumably from anaphase lag resulting in 
chromosome loss in one cell line), (ii) chromosome duplication (the underlying mechanisms of 
which are not well understood) or (iii) reciprocal chromosome loss and gain (resulting mainly 
from a mitotic nondisjunction event or potentially anaphase lag creating one cell line with 
chromosome loss and one with a reciprocal gain) (see figure 2). Following observations of 
increased incidence of chromosome loss in pre-implantation embryos compared to gains and 
the relative paucity of reciprocal events -which would indicate non-disjunction (Daphnis et al. 
2005; Delhanty 2005) the predominant mechanism leading to post-zygotic errors in human 
www.intechopen.com
 
The Role of Aneuploidy Screening in Human Preimplantation Embryos 
 
221 
embryos is likely to be chromosome loss resulting from anaphase lag (Coonen et al. 2004). 
Anaphase lag is described as the delayed movement during mitotic anaphase of a homologous 
chromosome resulting in it not being incorporated into the nucleus of the daughter cell. Often 
the lagging chromosome is lost creating one euploid daughter cell and a daughter cell with a 
monosomy for the chromosome in question. 
 
 
Fig. 2. Diagrammatic representation of anaphase lag (A) and mitotic nondisjunction (B), the 
two predominant types of mitotic errors in humans resulting in embryo mosaicism. 
Mosaicism is considered to be largely independent of age (Delhanty 2005). However, it has 
been shown that mosaicism originating by the mechanism of mitotic non-disjunction could 
perhaps be related to advanced maternal age (Munne et al. 2002). Results also suggest that 
mosaicism involving multiple chromosomes and a high proportion of cells (chaotic 
embryos) appear to impair early embryo development considerably.  
The general consensus for the viability of mosaic embryos is that, if more than half of the 
cells at day 3 post fertilization are aneuploid, the embryo is unlikely to be viable. 
Conversely, if a small proportion of cells are aneuploid in an otherwise healthy and euploid 
background, it is likely to be viable (Delhanty 2005).  
Clearly mosaicism affects embryo development making it a key element in the selection of 
embryos in clinical IVF cases (Bielanska et al. 2002; Delhanty 2005). 
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2.4 Abnormal fertilisation 
Abnormal fertilisation can also contribute to chromosome errors in pre-implantation 
embryos. Approximately 1% of conceptions contain more than two paired homologous sets 
of chromosomes-referred to as polyploidy rather than aneuploidy (Hassold 1986). There are 
two ways in which a polyploid embryo can arise: Firstly, if a diploid (2n) sperm or oocyte is 
involved in the fertilisation event and secondly, if two or more haploid sperm are involved 
in the fertilisation of a haploid oocyte (polyspermy). The majority of all polyploid embryos 
are the result of polyspermy and account for around 60% of polyploid conceptions (Egozcue 
et al. 2002). Following IVF with ICSI in which only a single sperm is inserted into each 
oocyte, the main mechanism leading to polyploidy in the embryo is the failure of the oocyte 
to extrude the second polar body (Grossmann et al. 1997). This results in a triploid  
embryo when fertilisation is achieved with a haploid sperm. Non-reduced or diploid sperm 
have also been shown to be involved in as many as 8.3% of polyploid conceptions  
(Egozcue et al. 2002). 
3. Aneuploidy and IVF development 
Since the first human IVF success in 1978 (Steptoe & Edwards 1978), advances in 
morphologic embryo grading and technologies aiding morphologic embryo selection have 
contributed to vastly improved IVF outcomes (Figure 3). Unfortunately, the morphological 
selection criteria for human gametes and embryos across all developmental stages have 
shown only weak correlations with aneuploidy (Munne 2006; Gianaroli et al. 2007; 
Alfarawati et al. 2011a). Karyotypic analysis indicates that there is a higher rate of 
chromosome abnormalities in morphologically abnormal monospermic embryos than 
morphologically normal embryos (Pellestor 1995; Almeida & Bolton 1996). However, clear 
distinctions cannot be made between chromosomally normal and abnormal human embryos 
by morphological assessment alone (Zenzes & Casper 1992). This may be because 
chromosome abnormalities detected at the early stages of embryogenesis cannot induce 
dysmorphism, since embryonic gene expression has not yet commenced (Braude et al. 1988; 
Tesarik et al. 1988). There is evidence from 24 chromosome copy number analysis that 
morphology and aneuploidy are linked at the later stages of pre-implantation embryo 
development (blastocyst stage). However, again the association is weak, and consequently, 
morphologic analysis can still not be relied upon to ensure transfer of chromosomally 
normal embryos. A significant proportion of aneuploid embryos are capable of achieving 
the highest morphologic scores even at the later stages of pre-implantation development, 
and, conversely, some euploid embryos achieve only poor morphological scores or even fail 
to develop (Alfarawati et al. 2011a).  
Other indirect aneuploidy screening methods have been trialled in the past with limited 
success. More recently, proteomic studies have shown to be a potentially useful tool in 
prenatal aneuploidy screening (Cho & Diamandis 2011; Kolialexi et al. 2011). By applying 
the same principle to pre-implantation embryos, one study has identified the first protein 
secreted by human blastocysts that is associated with generic chromosome aneuploidy 
(McReynolds et al. 2011). Although promising, this technology is still some way from 
becoming a routine aneuploidy screening test and oocyte or embryo biopsy with molecular 
cytogenetic analysis is still the preferred technique for PGS. 
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All molecular cytogenetic techniques involving gametes and embryos require direct access 
to the nuclear material of the gametes or blastomeres themselves. This process is achieved 
by cell biopsy and inevitably results in the destruction of the cells involved. With this in 
mind, it is important that fertilisation or embryogenesis is not compromised and the biopsy 
procedure impacts minimally on developmental potential. 
 
Fig. 3. Overall IVF and IVF/ICSI success rates by maternal age in the UK from 1992 – 2005. 
Figure adapted from Human Fertilisation and Embryology Authority website [ HFEA] 
(2008a)  
Recent clinical trials and meta-analyses of cases have suggested no benefit, and in some 
cases worse IVF pregnancy outcomes following PGS- presumably the result of discard of 
normal embryos (diagnosed as abnormal – false positives), detrimental effects of the biopsy 
including reduction of cellular mass and excessive micromanipulation outside of the 
incubator (Mastenbroek et al. 2007; Twisk et al. 2008). These results have however been 
dismissed by many PGS practitioners due to questionable experimental design (Munne et al. 
1999; Handyside & Thornhill 2007). Nevertheless, at the very least, these trials have 
reinforced the idea that embryo biopsy can only be justifiable when the benefit of the testing 
outweighs the cost to the embryo, since the ultimate aim of PGS is to identify 
chromosomally competent embryos without compromising embryo viability.  
4. Oocyte/embryo biopsy 
Biopsy for PGS is currently a two-step micromanipulation process involving the penetration 
of the zona pellucida followed by the removal of one or more cells for chromosome analysis. 
Breaching the zona is generally performed by laser ablation as it has been shown, when 
used appropriately, to have no detrimental effects on embryo development in both animal 
and human studies (Montag et al. 1998; Park et al. 1999; Han et al. 2003). Specialised 
micromanipulation pipettes are then used to separate the required cells from the oocyte or 
embryo. Theoretically, PGS can be accomplished at any developmental stage from the 
mature (MII) oocyte to the blastocyst stage. To date only three discrete stages have been 
proposed for clinical use: (i) polar body (oocyte and/or zygote), (ii) cleavage stage (day 3 
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embryo) and (iii) blastocyst (day 5 or 6 embryo). Each of these stages is biologically different 
thus having different diagnostic limitations in terms of information to be gained and impact 
on embryo viability. 
4.1 Polar body biopsy 
The removal of PB1 and/or PB2 from a human oocyte should have no deleterious effect on 
subsequent embryo, foetal and infant development as neither is required for successful 
fertilisation or embryogenesis (Gianaroli 2000; Strom et al. 2000). Biopsy and subsequent 
analysis of the first and second polar bodies allows the indirect interpretation of the 
chromosome complement of the corresponding oocyte thereby allowing the detection of 
maternally derived aneuploidy in resulting embryos (Verlinsky et al. 1996). While biopsy of 
PB1 alone and a combined PB1 and PB2 strategy have been used clinically for PGS, it is 
becoming increasingly evident that PB1 alone has limited applicability to PGS as only errors 
in MI can be detected and even MI chromatid segregation errors may not all be detected 
without analysis of both polar bodies. Indeed, as much as 30% of aneuploidy of maternal 
origin will not be diagnosed if only PB1 is sampled (Handyside et al. 2012). It is therefore the 
authors opinion that biopsy of both first and second polar body is essential for optimal 
detection of oocyte aneuploidy if used as an embryo selection tool. A further limitation is 
that cytogenetic analysis of either polar body does not allow the detection of aneuploidies of 
paternal origin nor aneuploidies arising after fertilisation in the embryo. 
The process of polar body biopsy is relatively labour intensive and may involve the 
micromanipulation of oocytes that ultimately do not develop into therapeutic quality 
embryos. Sometimes up to four manipulations - ICSI, PB1, PB2 and blastomere biopsy (as a 
reflexive test following test failure or an ambiguous PB result) may be required. However, in 
experienced hands, even 3 independent biopsy manipulations appear to have no deleterious 
effect on development (Magli et al. 2004; Cieslak-Janzen et al. 2006). Although simultaneous 
removal of PB1 and PB2 is possible on day 1 of embryo development (Magli et al. 2011) there 
may be advantages to sequential biopsy where PB1 is removed on day 0 (day of 
insemination) followed by the removal of PB2 on day 1. This is to avoid any degeneration of 
PB1 leading to possible diagnostic failure and also to allow for the distinction between polar 
bodies, thereby allowing accurate identification of errors in the first and second meiotic 
divisions. 
4.2 Cleavage stage embryo biopsy 
Historically cleavage stage biopsy was the most widely practiced form of embryo biopsy for 
PGS worldwide. This biopsy strategy is now becoming less popular however due to its 
potential detrimental effect on embryo viability and the problem of mosaicism in human 
cleavage stage embryos. A typical procedure for cleavage stage biopsy involves the removal 
of one or two blastomeres from an embryo on day 3 post-fertilization – usually those of 
suitable quality with at least 5 cells having entered the third cleavage division.  Although 
cleavage stage biopsy allows the detection of maternally and paternally derived aneuploidy 
as well as post-zygotic errors, they are not always distinguishable. The main problem 
affecting cleavage stage biopsy is chromosomal mosaicism resulting in an increased rate of 
false positive and negative results from single cell (or two cell) analysis (Figure 4). 
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Fig. 4. Schematic representation of possible misdiagnosis following cleavage stage biopsy of 
a single cell 
Data from studies comparing undiagnosed biopsied embryos and non-biopsied control 
embryos showed a detrimental effect of biopsy on implantation (Cohen & Grifo 2007; 
Mastenbroek et al. 2007), most evident in embryos of suboptimal quality. Animal models 
have shown that the potential for the embryo to continue to develop and implant is 
progressively compromised the greater the proportion of the embryo is removed (Liu et al. 
1993). While such evidence provides fuel for the argument against performing biopsy at 
early cleavage stages at all, evidence from frozen-thawed embryo transfers (as a proxy for 
biopsied embryos) in which successful implantations and live births can be achieved even 
following embryonic cell death  demonstrates that a certain degree of cell loss is tolerated 
(Cohen et al. 2007). However, just as in the animal models, success is inversely correlated 
with the amount of cellular mass lost. 
The successful application of cleavage stage biopsy minimising cell removal from good 
quality embryos shows it is compatible with normal embryo metabolism, blastocyst 
development and foetal growth (Hardy et al. 1990). Moreover, studies of pregnancies and 
children born after cleavage stage biopsy have identified no significant increase in 
abnormalities above the rate seen in routine IVF (Harper et al. 2006; Banerjee et al. 2008; 
Nekkebroeck et al. 2008). 
A general estimate therefore is that cleavage stage biopsy of 1 cell may reduce the 
implantation potential of an IVF embryo of around 10% although this figure would 
inevitably increase in less experienced hands (Cohen & Grifo 2007). The challenge for any 
future application of cleavage stage biopsy PGS therefore is to ensure that any benefits 
outweigh these costs and it remains a question whether this will be possible even with more 
accurate and reliable tests given the high levels of mosaicism. 
4.3 Blastocyst stage biopsy 
Blastocyst biopsy involves the sampling of trophectoderm (TE) cells, the spherical outer 
epithelial monolayer of the blastocyst stage embryo. Just as at cleavage stage, TE biopsy is 
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able to detect aneuploidy arising in either gamete or post-fertilisation. It is more akin to 
early prenatal diagnosis when compared to the other biopsy stages as it involves the 
removal of up to 10 cells without depleting the inner cell mass (ICM) from which the foetus 
is derived. TE biopsy is most commonly achieved by partial zona dissection followed by a 
period of culture in which time the expansion of the blastocyst will cause herniation of 
several cells through the artificial breach. The herniating cells (~4-10 cells) are then easily 
removed by excision or aspiration using micromanipulation tools with or without the aid of 
a laser. Sampling of several cells at this stage lessens the likelihood that mosaicism will 
produce false positive results also overcoming the limitations of extreme sensitivity 
apparent with conventional single cell diagnosis. 
As with cleavage stage biopsy, it has been suggested that the removal of cells may 
negatively impact on the embryo’s developmental potential. However, skilled biopsy 
practitioners are able to remove TE cells and achieve comparable implantation rates to non-
biopsied blastocyst stage embryos (Kokkali et al. 2007). It has also been proposed that 
sampling of the TE may not reflect the genetic composition of the ICM (Kalousek & 
Vekemans 1996). Recent data however comparing TE to ICM suggests 100% concordance 
with the exception of structural abnormalities (Johnson et al. 2010a). 
Currently the main limitation of blastocyst biopsy is the low number of embryos that reach 
the blastocyst stage; a number that significantly decreases with advanced maternal age 
(Pantos et al. 1999). If very few blastocysts are available, particularly in older patients, biopsy 
for selection purposes may be of no benefit. Also, time constraints at the blastocyst stage 
dictate, in many cases, the need to cryopreserve biopsied blastocysts awaiting diagnosis. 
Thus, the effect of cryopreservation and subsequent thawing on embryo viability must be 
taken into account. Nonetheless, improved culture techniques, possible vitrification and 
rapid molecular analysis regimes are making blastocyst biopsy an increasingly attractive 
option (Schoolcraft et al. 2010). 
5. Molecular cytogenetics – The rise and fall of fluorescence in situ 
hybridization (FISH) in PGS 
Following embryo or oocyte biopsy, PGS requires cytogenetic techniques with high 
sensitivity and specificity to establish the chromosome composition of the embryo via the 
analysis of one or very few cells. Classic karyotyping techniques are not suitable for pre-
implantation testing due to the difficulty of achieving good metaphase spreads with the 
limited cells available for testing (Angell et al. 1986; Papadopoulos et al. 1989). In 1993 the 
application of Fluorescent In-situ Hybridisation (FISH) for the single cell detection of the sex 
chromosomes in pre-implantation embryos provided a springboard for aneuploidy 
detection and clinical application of PGS soon followed (Griffin et al. 1992). FISH is a highly 
sensitive, relatively inexpensive molecular cytogenetic tool enabling the determination of 
chromosome copy number at the single cell level. Its successful application rapidly led to 
the implementation of PGS as a clinical adjunct to IVF globally. To date tens of thousands of 
PGS cases have been performed globally, attesting to its popularity. Nonetheless, advances 
in technology are making FISH for PGS in oocytes and embryos a less attractive option due 
to a range of technical and biological considerations that are becoming increasingly 
apparent (Table 1). 
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Table 1. Scope and limitations of different  molecular cytogenetic techniques after embryo 
biopsy 
5.1 Fluorescent In-situ Hybridisation (FISH) 
FISH requires the fixation of biopsied cells to a glass slide before visual analysis of 
hybridised fluorescent chromosome specific DNA probes. The advantage to the observer of 
being able to view the presence of chromosome copy number directly is considerable. 
Technical issues however include the fact that FISH signals can overlap (making two signals 
appear as one, or three as two) or “split” according to the stage of the cell cycle making a 
single signal appear as two (Cohen et al. 2009). Initially only five different fluorescent probes 
attached to different chromosomes (typically 13, 16, 18, 21, 22 or 13, 18, 21 X and Y) were 
used, however a recent study analysing twelve chromosomes (X, Y, 2, 4, 13, 15, 16, 18, 19, 20, 
21, 21) at the cleavage stage described detection of 91% of chromosomally abnormal 
embryos reaching the blastocyst stage. In this case, if the misdiagnosis rate of each probe 
averaged 1%, over the two rounds of hybridisation required, an accuracy of only 88% per 
embryo could be achieved. The test’s ability to diagnose only 91% of aneuploid embryos 
compounded by the 12% misdiagnosis rate per embryo would result in only 80% efficiency 
of the test in its ability to diagnose aneuploidy per embryo. This would inevitably result in 
the transfer of aneuploid embryos (false negative) or the discarding of euploid embryos 
(false positive).  It has been widely accepted that the efficiency of each probe is reduced in 
subsequent hybridisation rounds (Harrison et al. 2000) however a 24 chromosome FISH 
assay has recently been applied to preimplantation human embryos with no apparent loss of 
signal, even after four rounds of hybridization (Ioannou et al. 2011). 
The importance of low error rates on the diagnostic efficiency of PGS is strongly argued 
(Summers & Foland 2009; Munne et al. 2010), as is the need to detect all chromosomes 
simultaneously for aneuploidy.  Notwithstanding the ability now to detect all 24 
chromosomes by FISH, the issues of mosaicism, signal interpretation, clinical trial data and 
the development of microarray based methods for detecting 24 chromosome copy number 
are now signalling the demise of FISH based PGS approaches. Microarray based tests are 
now becoming the standard and these have been made possible through the advancement 
of whole genome amplification (WGA) technology. 
5.2 Whole genome amplification (WGA) 
The introduction of whole genome amplification (WGA) techniques has led to new more 
efficient 24 chromosome molecular karyotyping tests. WGA brought with it the potential to 
increase the amount of cytogenetic information that can be obtained from a single nuclear 
parent of origin MI or MII
Fluorescence in situ 
hybridization (FISH)
5 to 12 low no yes no no no
Array comparative genomic 
hybridisation (aCGH)
24 high no no no no no
Single nucleotide 
polymorphism (SNP) array
24 highest yes yes yes yes
limited to 
hyperploidy
Parental DNA 
required
Origin of aneuploidyChromosomes 
detected
Resolution
Recombination 
mapping
Polyploidy
Test
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genome contained in one cell. A single cell contains 6pg of DNA, far less than the 0.2-1.0µg 
usually required for microarray analysis and thus the need for amplification is paramount 
(Wells & Delhanty 2000). The process simply involves the transfer of the cell(s) to a 
microfuge tube followed by cell lysis prior to genome amplification either by polymerase 
chain reaction based methods or,  more recently, multiple displacement amplification 
(MDA) to yield quantities of DNA in excess of 20 µg from a single cell. These products can 
in turn be used for genome wide analysis studies to establish chromosome copy number 
with impressive accuracy. One of the biggest drawbacks of single cell DNA amplification is 
a phenomenon known as allele dropout (ADO) where only one of the two alleles at a locus 
successfully amplifies (Walsh et al. 1992; Findlay et al. 1995; Piyamongkol et al. 2003). This 
proved a limiting factor on the resolution and reliability of PGD for single gene disorders 
where individual gene sequences are analysed but is less of an issue for array based PGS 
where many probes along each chromosome are used (Ling et al. 2009). Further problems 
involving the extreme sensitivity of single cell analysis still exist in the form of failed or poor 
amplification. However, these failure rates can be maintained at under 3% in experienced 
laboratories (Gutierrez-Mateo et al. 2011).  
5.3 Comparative genomic hybridisation (CGH) 
Originally designed for molecular karyotyping of tumour cells (Kallioniemi et al. 1992; 
Kallioniemi et al. 1993), comparative genomic hybridisation (CGH) has been successfully 
adapted for the analysis of human polar bodies and pre-implantation embryonic cells 
(Voullaire et al. 2000; Wells et al. 2002). Originally a labour intensive and time consuming 
procedure involving hybridization to and analysis of standard cytogenetic metaphase 
chromosome preparations, CGH was adapted for use in microarray technology, which 
allowed streamlining of the process. Recent successful applications of the technology  
have enabled array CGH (aCGH) to become the current platform of choice for PGS at all 
biopsy stages in the majority of laboratories around the world (Hellani et al. 2008; Alfarawati 
et al. 2011b). 
The process involves the separate labeling of the amplified DNA and normal reference 
sample using different fluorescent dyes followed by co-hybridization to several thousand 
probes derived from known regions of the genome printed on a glass slide. Using 
quantitative image analysis, differences in the fluorescence ratio are interpreted to identify 
gained or lost regions along all chromosomes simultaneously with an error rate of less than 
2% (Gutierrez-Mateo et al. 2011). The main technical limitations of this process are (i) that it 
does not supply information about chromosomal ploidy per se, only deviations from the 
most frequent level of the combined fluorescence signal and (ii) the origin of the error is not 
determined. Thus haploid and polyploid embryos will appear diploid or ‘normal’ and 
meiotic errors are not distinguished from post-zygotic ones. Despite these limitations, aCGH 
is rapidly establishing itself as the “gold standard” for PGS, replacing FISH based 
approaches in most laboratories. 
5.4 Single Nucleotide Polymorphism (SNP) arrays 
Single Nucleotide Polymorphisms (SNPs) are the most frequent form of DNA variation in 
the genome. To date over 6 million SNPs have been identified in the human genome (Javed 
& Mukesh 2010). SNPs are bi-allelic genetic markers that can be used in a variety of ways to 
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detect chromosome copy number. SNP micro-arrays are used to detect the specific alleles 
present in polar bodies or embryos at up to 500,000 SNP loci. This information can, in turn, 
be interpreted in several ways to obtain massive amounts of genetic information. Simple 
quantification of the SNP alleles and analysis of heterozygosity enables diagnosis of 
aneuploidy including uniparental isodisomy (Northrop et al. 2010; Brezina et al. 2011; Treff 
et al. 2011). Using this method, results can be difficult to interpret above the level of 
background ‘noise’ due to the problem of amplification from a single template. For this 
reason, methods involving comparison with parental DNA are under development 
(Handyside et al. 2010; Johnson et al. 2010b). Since all embryonic chromosomes are derived 
from parental chromosomes, predicted genotypes based on known parental data can be 
used to “clean” noisy single cell data resulting in a comprehensive and highly reliable 
molecular cytogenetic test for chromosome copy number (Johnson et al. 2010b). In addition 
to this, again with the aid of the known parental genotypes, our group has developed a test 
involving Mendelian inheritance analysis of SNPs known as ‘Karyomapping’. By 
establishing the four parental haplotypes, only informative ‘key’ SNPs are analysed to 
establish chromosome copy number, parental origin and points of meiotic recombination of 
the tested cells can be ‘Karyomapped’(Handyside et al. 2010). Karyomapping has the added 
advantage of being able to detect not only meiotic aneuploidy but also the presence of the 
chromosomes carrying the mutant allele for cases involving the risk of transmission of 
specific known inherited disorders. 
SNP genotyping has the potential to be the most comprehensive platform for PGS. The 
interpretation of a SNP genotype allows diagnosis of all possible chromosome copy number 
aberrations. It has the capacity to perform as a high resolution molecular cytogenetic test at 
higher resolution than aCGH for all types of chromosomal gains and losses and with the 
added ability of linkage based analysis allowing diagnosis of inherited genetic disease 
(Handyside et al. 2010). Although largely clinically un-validated, comparative data with 
other platforms suggest better efficiency than both FISH and aCGH for aneuploidy 
screening (Johnson et al. 2010b; Treff et al. 2010a; Treff et al. 2010b). Recently presented 
clinical data of SNP array based PGS on cleavage stage embryos suggests significant 
improvement of pregnancy rates following embryo transfer (Rabinowitz et al. 2010).We 
anticipate that with further clinical validation, SNP genotyping will become the gold 
standard for PGS  in the near future. 
6. What we have learnt from PGS thus far? 
The rationale for PGS is of course that if embryo ploidy could be determined and euploid 
embryos selected for embryo transfer, IVF pregnancy rates would increase and poor 
outcomes such as implantation failure and miscarriage would decrease. Few disagree with 
this premise underpinning PGS as scientifically and clinically sound. 
Since its inception in the mid-90s, PGS has primarily involved the biopsy of one or two 
cells on the third day of embryo development followed by targeted chromosome analysis 
using FISH. Subsequently, diagnosed euploid embryos (for the limited number of 
chromosomes analysed) were transferred or cryopreserved with the remaining embryos 
diagnosed as aneuploid being discarded (with or without follow-up confirmation 
analysis). This work was based on the theoretical premise of PGS without the support of 
randomised controlled trials (RCTs). All recent RCTs using cleavage stage biopsy 
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followed by FISH analysis showed no improvement in delivery rates after PGS with some 
even suggesting adverse outcomes (Staessen et al. 2004; Mastenbroek et al. 2007; Blockeel 
et al. 2008; Hardarson et al. 2008; Mersereau et al. 2008; Debrock et al. 2010). The largest of 
these trials included over 200 patients in each of the experimental arms (control and 
treatment groups) and concluded that PGS resulted in a reduced delivery rate following 
IVF (Mastenbroek et al. 2007). These results, contrary to the original premise of PGS, 
sparked much debate with several institutions including the practice committees of the 
Society of Assisted Reproductive Technology and the American Society of Reproductive 
Medicine [SART & ASRM] (2008b) and the British Fertility Society (Anderson & Pickering 
2008) issuing statements that PGS should no longer be performed. Meanwhile, several 
groups criticised the trials for their poor diagnostic efficiency, practical skill levels, 
inappropriate patient selection and generally low pregnancy rates. They claimed that the 
trials were performed by inexperienced practitioners thereby generating invalid or 
questionable results (Cohen & Grifo 2007; Simpson 2008). 
What is not in question is that these trials have ultimately highlighted the complexity of 
considerations PGS requires when applied clinically. FISH of cleavage stage biopsies has 
clearly outlined that both technical and practical limitations exist when performing PGS to 
improve pregnancy outcomes. Furthermore, there is great importance and careful 
consideration needed in patient selection as well as effective test selection and 
implementation on a case-by-case basis (Handyside & Thornhill 2007). 
The success of aneuploidy screening as a selection tool for IVF to improve pregnancy rates is 
dependent on the efficacy of the entire testing process. It is now clear that FISH, especially 
for cleavage stage biopsy, is not the optimal tool for PGS. The process is subject to the 
following technical limitations: (i) the efficacy of the cell preparation technique, (ii) the 
accuracy of the FISH test itself and its reliable interpretation. Biologically, we are 
constrained by the products we have to work with (embryo quality, mosaicism and 
nucleation) and the time in which to work with them. We believe that there is scope for PGS 
to improve pregnancy rates in ART but the test used must be optimised and tailored to suit 
the biological and technical limitations that exist to maximise benefit at the lowest possible 
cost to the embryo.  
7. Clinical applications and decision making 
Aneuploidy screening using 24 chromosome micro-array analyses should improve IVF 
outcomes with the implementation of case-by-case cost-benefit analysis. For best results, 
PGS should be performed with the most comprehensive cytogenetic platform available. PGS 
is considered too invasive to be employed as a routine embryo selection tool for IVF thus, at 
present, it should be offered only to patients at high risk of aneuploidy. The cost of the 
biopsy on embryo development is only justifiable if the information gained will outweigh 
the cost to the cohort of embryos as a whole. For this reason, false positive results due to 
mosaicism and the number of testable embryos in a cohort are important in the decision 
making process. Advanced maternal age (AMA) is the single largest indication for PGS as 
an adjunct to embryo selection to improve IVF success. Careful patient selection is still 
required within this group of patients to achieve the best results (see figure 5). There are a 
number of other indications for which PGS is likely to be of most benefit, all of which are 
associated with a potential increased risk of aneuploidy including patients with Repeated 
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Implantation Failure (RIF) and Recurrent Miscarriage (RM). Patients with diagnosed high 
levels of sperm aneuploidy or severe male factor infertility may also benefit.  
PB biopsy theoretically has the lowest cost to embryo development but only gives 
information about maternally derived aneuploidy. PB biopsy is therefore of most benefit  
to patients of AMA with no other suspected aneuploidy input. Both PB1 and PB2 should  
be sampled to ensure that the majority of maternally aneuploidy is detected (Geraedts  
et al. 2011). 
Theoretically, blastocyst stage biopsy is the optimal stage as it partially negates the problem 
of mosaicism and gives maximum aneuploidy information from maternal, paternal and 
post-zygotic events. In addition, the biopsy of 10 or more cells virtually eliminates  the 
problem of ADO following WGA (Ling et al. 2009).  However, the logistical downside is that 
embryos may need cryopreservation whist awaiting genetics results, a potential additional 
‘cost’ to embryos. Furthermore, in- vitro blastocyst development may be limited in some 
patients leading to a limited cohort of blastocysts that can be biopsied simultaneously 
reducing the chance of a live birth and genetic information from the cohort (Janny & 
Menezo 1996). Thus it should only be considered for patients with RIF and RM, including 
male factor, with evidence of good blastocyst formation or proven fertility. 
 
 
 
Fig. 5. Three distinct patient groups in relation to age and IVF success rates. Note the drop in 
success rates beyond maternal age 35 across all years (consistent with increasing rates of 
aneuploidy). High number of embryos and low rate of aneuploidy are expected in patient 
group under 35 years of age (1) thus PGS is not recommended - Cost outweighs benefit of 
PGS. Moderate embryo numbers and increased rate of aneuploidy consistent with reduced 
IVF success rates of patients above 35 years (2) indicate a target group for PGS - Benefit of 
PGS outweighs its cost. PGS is suggested to be of no benefit for embryo selection in patients 
of severe AMA due to low number of embryos and high rate of aneuploidy (3) - Cost 
outweighs benefit of PGS. 
Figure adapted from Human Fertilisation and Embryology Authority website  [ HFEA] 
(2008a)  
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The inherent problem of mosaicism and false positive results is a major problem for biopsy 
at the cleavage stage. This, paired with the cost of removing a significant amount of the cell 
mass (up to 25%), suggests that use of cleavage stage biopsy should be limited to cases of 
male factor aneuploidy with known poor ability for blastocyst development. Removal of 
only a single cell is recommended to minimize cost to the embryo and prevent the dilemma 
of discordant results due to mosaicism (Cohen et al. 2007). Cleavage stage biopsy may also 
be considered as follow-up for equivocal results from PB biopsy (Magli et al. 2004; Cieslak-
Janzen et al. 2006). The relative pros and cons of all biopsy stages are summarised in table 2. 
Biopsy, irrespective of stage, should only be performed if there are a sufficient number of 
oocytes or embryos to be tested. If there is limited or no embryo selection to be achieved by 
PGS then it (PGS) should be avoided as there will be no benefit to IVF success rates and may 
even be a detrimental effect (Summers & Foland 2009). An exception to this is when PGS is 
used not as an embryo selection tool but as a diagnostic tool to avoid or diagnose aneuploidy.  
 
 
Table 2. Technical limitations, costs and benefits of the established biopsy stages for PGS 
Some patients may require elimination of the possibility of aneuploidy resulting in poor 
outcomes such as miscarriage or birth of a child with a genetic defect. These ‘must screen’ 
patients for PGS should be considered more like diagnosis of inherited genetic disease and 
all embryos, irrespective of the number and quality, should be tested. 
8. Research and future developments 
It is now well documented when and how extra or missing chromosomes arise but the big 
question remains ‘why’. Clearly, research into the origin of human aneuploidy will continue 
to provide new and exciting insights in the field of reproductive medicine. The introduction 
of new array technology, including SNP genotyping of embryos, will further improve PGS 
strategies. For example, recent evidence demonstrating that errors are equally likely during 
the two maternal meiotic divisions (Handyside et al. 2012) is rapidly leading to a shift in the 
MI MII MI MII
PB1 yes no no no no no
Day 0           
(day of fertilisation)
Minimal manpulations.                              
No removal of viable cells.                           
Maximum time for analysis prior to 
embryo transfer.
Only information from maternal MI.
PB1 & PB2 yes yes no no no no Day 0 and 1
No removal of viable cells.                       
Maximum time for analysis prior to 
embryo transfer.
Only information for maternal meiotic 
errors.
Cleavage stage 
(blastomere)
yes yes yes yes yes
no               
(Yes with limited 
sensitivity if >1 cell 
analysed)
Day 3
Information for all origin of 
aneuploidy.                                        
Maximise number of embryos tested.     
Paternal aneuploidy detected.                   
Mosaicism resulting in false positive 
and negative results.                                       
Removal of significant proportion of 
cell mass.
Blastocyst stage 
(trophectoderm)
yes yes yes yes yes
yes              
(only with limitation 
on sensitivity)
Days 5 and 6
Information for all origin of 
aneuploidy.                                                          
Biopsy of several cells (~10 cells).              
No harm to ICM.                                                
Paternal aneuploidy detected.
Reduced number of embryos for 
testing (requires good blastocyst 
formation).                                                         
Reduced time for diagnosis (embryo 
cryopreservation potentially nececary). 
Maternal Paternal
origin of aneuploidy Associated costs and benefits
Post Zygotic Benefit
Detection of 
mosaicism Cost
Day of biopsy -
days post 
fertilisationBiopsy stage
cessary 
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strategy for approaching polar body analysis for PGS with PB1 considered inadequate if 
embryo selection is the ultimate goal.  
Continued efforts should be employed to use new technologies to correlate the rate and 
origin of aneuploidy with external factors in an effort to identify markers for aneuploidy 
risk. Patient assessment of these risk factors will lead to better personalisation of PGS 
treatment plans and provide an understanding of the underlying mechanisms behind 
chromosome segregation and the cause of aneuploidy. 
Along with AMA, altered recombination in meiosis is the most important known aetiology 
related to aneuploidy and gives clues to the overall mechanism (Hassold et al. 2007). 
Algorithms applied to SNP genotyping data, including Karyomapping can be applied for 
high resolution pinpointing of recombination points (Handyside et al. 2010; Gabriel et al. 
2011a). Patterns of recombination across the genome can then be correlated with 
chromosome mal-segregation in meiosis in an attempt to find aberrant patterns that 
predispose to aneuploidy. Similar strategies can be employed to different patient profiles to 
ascertain further aetiologies associated with aneuploidies of different origin.  Further 
understanding of the predisposition to human aneuploidy will lead to specific patient 
treatment and more importantly guide the direction of studies on the molecular basis of 
aneuploidy. Once the mechanisms leading to aneuploidy are understood and there is an 
understanding of why it occurs, interventions to prevent aneuploidy could be usefully 
investigated. 
It has been hypothesised that the high rates of aneuploidy and mosaicism following IVF 
procedures may in fact be an iatrogenic artefact of the procedure itself. Ovarian 
hyperstimulation  (Baart et al. 2007),  fertilisation in vitro (Bean et al. 2002) and in vitro 
culture environments (IVC) (Carrell et al. 2005; Sabhnani et al. 2011; Xu et al. 2011) appear to 
affect embryo aneuploidy. A recent RCT of ovarian stimulation protocols revealed that 
minimal stimulation, although associated with a reduced number of oocytes, results in 
higher proportions of chromosomally ‘normal’ embryos. It was hypothesised that 
conventional stimulation protocols result mainly in an increase of post zygotic chromosome 
segregation errors. Altered ovarian function (recruitment of follicles), gonadotrophin dose 
and GnRH analogue have been offered as potential correlates for further investigation. 
Furthermore, mouse studies have shown increased meiotic and post zygotic error rates 
following IVF and IVC respectively (Bean et al. 2002; Sabhnani et al. 2011). The sensitivity of 
mouse oocytes to different culture regimens resulting in differing aneuploidy rates 
corroborate the hypothesis that IVF affects aneuploidy (Carrell et al. 2005). In humans, FSH 
levels associated with in-vitro maturation correlate with chromosome mal-segregation in the 
first meiotic division (Xu et al. 2011). Animal models could be further employed for 
manipulation of IVF parameters in an effort to induce or suppress aneuploidy, although 
clinical IVF itself may provide the best ‘experiment’ to gain a better understanding of the 
mechanisms involved in human aneuploidy. 
Full genetic sequencing seems the logical next technological advance for PGS and appears 
technically possible following successful genomic sequencing of microbial single cells 
(Zhang et al. 2006; Lasken 2007). Additional data at the highest possible resolution should 
inevitably prove more reliable for chromosome copy number analysis and, as with SNP 
genotyping, points of recombination as well as points of partial aneuploidy along 
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chromosomes could be analysed with more precision. Currently,  increased resolution of 
PGS is limited by the WGA step (Ling et al. 2009). Achieving the highest possible resolution 
is directly restricted by the phenomenon of ADO when amplifying single or very few cells. 
Thus it necessary to invest effort in improving WGA technology before the full benefits of 
genomic sequencing could be realised. 
With the increasing amount of data obtained from PGS technologies comes the issue of an 
increasing amount of ‘incidental’ findings of unknown pathological significance.  Careful 
considerations of the social, ethical and legal aspects of these findings are required to 
combat potential problems prior to implementing higher resolution technologies.  
The ultimate goal of PGS is to provide maximum benefit (in terms of information to the 
parent/healthcare provider) with minimal cost to the embryo. The possibility of gaining 
chromosome copy number information with no cost to the embryo would enable PGS to be 
used routinely as an embryo selection tool for IVF. An indirect aneuploidy screening test 
was first explored by associations with conventional embryo morphology scoring. However, 
morphological embryo grading is apparently at its limits to improve IVF success rates and 
has only shown very limited correlation with aneuploidy (Munne 2006; Gianaroli et al. 2007; 
Alfarawati et al. 2011a). The implementation of time-lapse imaging to embryo culture has 
facilitated high resolution morphokinetic analysis of embryo development in an attempt to 
improve IVF success rates and eliminate potentially abnormally developing embryos. 
Morphokinetic analysis involves continual analysis of the morphological state and rates of 
change during oocyte and embryo development and provides evidence of developmental 
milestones that can predict embryo implantation (Meseguer et al. 2011).  Since, cells of 
different genotypes are known to have slightly different cell cycle times (Varrela et al. 1989), 
it follows that  algorithms involving multiple developmental time points could be used to 
predict embryo aneuploidy at no cost to the embryo. Embryos with an abnormal karyotype 
(particularly those with multiple abnormalities) may have aberrant cell cycles, detectable by 
morphokinetic analysis, compared with normal embryos. New studies into the 
morphological rates of change including such developmental markers as PB extrusion, 
syngamy and early mitotic divisions could find more significant correlations with 
chromosome mal-segregation than embryo morphology alone. 
Other approaches to non-invasive assessment of embryo viability include the measurement 
of what is used by or what is secreted by the oocyte or embryo. All culture media contain 
substances that are required for embryo development. Culture media will also contain all 
products secreted by the oocyte or embryo. Levels of these can be measured in a variety of 
ways to establish embryo viability (for review see Aydiner et al. 2010).  
Analysis of spent culture media is an area already being explored as potential for a new 
indirect PGS platform. A recent study analysing uptake patterns of amino acids has shown 
that regulation of amino acid metabolism correlates with embryo aneuploidy. The study 
using FISH analysis of five chromosomes (13, 18, 21, X and Y) demonstrated altered amino 
acid turnover in embryos with grossly abnormal karyotypes when compared to genetically 
normal embryos (Picton et al. 2010). Although promising, these early data lack specificity 
and further work is needed to more accurately establish how embryo metabolism may be 
indicative of its chromosomal complement. Precise metabolic profiling of embryos with 
known copy number aberrations is proposed as a specific experiment to establish more 
meaningful correlations. 
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A further approach is based on the hypothesis of altered gene expression and protein 
synthesis of chromosomally abnormal embryos.  One study, using a proteomic approach, 
has identified the first protein secreted by human blastocysts (Lipocalin-1) that is associated 
with generic chromosome aneuploidy (McReynolds et al. 2011) promising the biggest step to 
date towards a non-invasive PGS test.  
9. Conclusion 
PGS has proved to be one of the most controversial areas of reproductive medicine in recent 
times. The entire community is united in its collective will to improve IVF success, reduce 
miscarriage rates and ensure that couples avoid children with developmental abnormalities. 
The means by which this is achieved remains the subject of intense debate. What can be 
clear however is that the controversy will serve to increase the interest in PGS leading to 
new and radical future treatments. 
10. List of abbreviations 
aCGH Array comparative genomic hybridisation 
ADO Allele dropout 
AMA Advanced maternal age 
CGH Comparative genomic hybridisation 
DNA Deoxyribonucleic acid 
FISH Fluorescence in-situ hybridization 
ICM Inner cell mass 
IVF In-vitro fertilisation 
IVC In-vitro culture 
MDA Multiple displacement amplification 
MI First meiotic division (Meiosis 1) 
MII Second meiotic division (Meiosis 2) 
PB Polar body 
PB1 First polar body  
PB2 Second polar body 
PGS Preimplantation genetic screening (for aneuploidy) 
PS Premature/precocious separation of sister chromatids 
SNP Single nucleotide polymorphism 
TE Trophectoderm 
WGA Whole genome amplification 
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